

AroCell AB has submitted a new patent application: "Predicting Patient Survival"

AroCell announced today that a patent application has been submitted regarding the use of an immunoassay of Thymidine Kinase 1 (TK1) to enable more accurate prognoses in prostate cancer patients. The patent is based on research together with the University of Tampere.

In the study, on which this patent application is based, TK1 protein levels were assayed with AroCell TK 210 ELISA in serum samples collected from subjects with newly diagnosed prostate cancer and compared with the extent and speed of disease progression over a period of 10 years. The study was executed in collaboration with the Prostate Research Center at Tampere University Hospital and coordinated by Professor Teemu Murtola of the Pharmacoepidemiology and Chemoprevention of Urological Cancer Research Group.

"Thymidine kinase 1 in serum predicted survival after prostate cancer diagnosis, demonstrating independent predictive value over established clinical risk factors. If confirmed in further and larger studies, this biomarker could be incorporated in prostate cancer risk stratification when selecting optimal treatment and surveillance schedule." says Professor Teemu Murtola.

"Prostate cancer is one of the most common cancers in men and this patent strengthens AroCell's position as a developer and promoter of novel biomarkers for monitoring cancer. The patent will reinforce our position and increases AroCell's attractiveness as a business partner. We will continue to develop our proprietary portfolio to further expand our business opportunities." says Michael Brobjer, CEO AroCell.

There is a recognized need for better prognostic tools in prostate cancer. For many men, the disease will take a benign course and therefore there is a need to avoid over-treating these patients while providing more accurate monitoring of those with active disease. This is especially important with the advent of new and more effective therapies for prostate cancer.

Contacts

Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
E-mail: michael.brobjer@arocell.com

About Thymidine Kinase 1

Thymidine Kinase 1 (TK1) is a key enzyme in DNA precursor synthesis. It is upregulated during the late G1 phase and early S phase of the cell cycle and its presence in cells is an indicator of active cell proliferation. Increased levels of TK1 in the blood can indicate active cell proliferation as a consequence of abnormal cell turnover and cell disruption triggered by for example therapeutic agents.

About TK 210 ELISA

AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood. The ELISA format is simple and robust, requires no special instrumentation to perform and can easily be incorporated into standard laboratory processes. By utilizing monoclonal antibodies specific for the TK1 epitope TK 210, AroCell TK 210 ELISA brings improved sensitivity and specificity to the assay of this key biomarker. AroCell TK 210 ELISA provides new opportunities for studying cellular proliferation, disruption, and monitoring of therapy response and relapse in subjects with haematological and solid tumours.

About Tampere University Hospital

Tampere University Hospital (TAYS), Tampere, Finland, is a world leader in research into prostate cancer. Its mission is to leverage basic sciences, epidemiology, computational biology, and clinical practice to find answers enabling better management of prostate cancer.

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2020-01-30 14:27 CET.

Attachments

[AroCell AB has submitted a new patent application: "Predicting Patient Survival"](#)